Compare · BBC vs HCXY
BBC vs HCXY
Side-by-side comparison of Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Hercules Capital, Inc. (HCXY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BBC and HCXY operate in n/a (n/a), so they compete in similar markets.
- HCXY carries a market cap of $4.52B.
- Over the past year, BBC is up 99.6% and HCXY is down 0.5% - BBC leads by 100.1 points.
Virtus LifeSci Biotech Clinical Trials ETF
The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Clinical Trials Index. Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.
Latest BBC
Latest HCXY
- Hercules Capital Announces Date of 2026 Annual Meeting of Stockholders
- Hercules Capital Reports First Quarter 2026 Financial Results
- Hercules Capital Enters Next Phase of Growth with Expanded Leadership Team
- Hercules Capital Declares a Total Cash Distribution of $0.47 per Share for the First Quarter 2026
- Hercules Capital Announces Date for Release of First Quarter 2026 Financial Results and Conference Call
- Hercules Capital Sets New Record with All-Time High New Debt and Equity Commitments
- Hercules Capital Receives a BBB (high) Affirmed Investment Grade Corporate and Credit Rating from Morningstar DBRS
- Hercules Capital Named 2025 Americas BDC Manager of the Year by Private Debt Investor
- Hercules Capital Reports Fourth Quarter and Full-Year 2025 Financial Results
- Hercules Capital Closes Institutional Notes Offering of $300.0 Million 5.350% Unsecured Notes due 2029